Compare Amylx Pharmaceuticals Inc (AMLX) vs Equinor ASA (EQNR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Equinor ASA — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Equinor ASA trades at $34.28 (market cap $78.18B). The key difference: Equinor ASA is far larger — about 39.5× Amylx Pharmaceuticals Inc's market cap, and Equinor ASA pays a 4.48% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EQNR | |
|---|---|---|
Market Cap | $1.98B | $78.18B |
Sector | Health | Energy |
52-Week High | $18.70 | $42.40 |
52-Week Low | $7.64 | $22.41 |
Enterprise Value | $1.70B | $89.94B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Equinor (EQNR) trades at $33.92, down 0.26% today, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program. Valuation ratios appear attractive with a P/E of 15.35 and EV/EBITDA of 2.27, though net income margin has declined to 5.3% in 2025 from 19.29% in 2022.
EQNR presents a value opportunity with low valuation multiples and ongoing shareholder returns via dividends and buybacks. However, declining profitability and negative net cash flow trends pose risks. Analyst sentiment is mixed with 30% buy ratings but 57% hold, suggesting cautious optimism. Key catalysts include production growth from recent investments, while oil price volatility and execution risks remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
